Коморбидность хронической обструктивной болезни легких и сердечно-сосудистой патологии: современное состояние проблемы

1. Xiang Y., Luo X. Extrapulmonary comorbidities associated with chronic obstructive pulmonary disease: A review. Int J Chron Obstruct Pulmon Dis. 2024; 19: 567–78.

https://doi.org/10.2147/COPD.S447739. PMID: 38476124. PMCID: PMC10927883.

2. Wang Z., Lin J., Liang L. et al. Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: An analysis for the Global Burden of Disease Study 2021. Respir Res. 2025; 26(1): 2.

https://doi.org/10.1186/s12931-024-03051-2. PMID: 39748260. PMCID: PMC11697803.

3. World Health Organization. Chronic obstructive pulmonary disease (COPD), 6 November 2024. URL: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (date of access – 03.03.2025).

4. Клинические рекомендации. Хроническая обструктивная болезнь легких. Ассоциация врачей и специалистов медицины труда, общероссийская общественная организация «Российское научное медицинское общество терапевтов», Российское респираторное общество. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 603_3. Доступ: https://cr.minzdrav.gov.ru/preview-cr/603_3 (дата обращения – 03.03.2025). (Clinical guidelines. Chronic obstructive pulmonary disease. Association of doctors and specialists in occupational medicine, Russian Scientific Medical Society of Internal Medicine, Russian Respiratory Society. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 603_3. URL: https://cr.minzdrav.gov.ru/preview-cr/603_3 (date of access – 03.03.2025) (In Russ.)).

5. Celli B., Fabbri L., Criner G. et al. Definition and nomenclature of chronic obstructive pulmonary disease: Time for its revision. Am J Respir Crit Care Med. 2022; 206(11): 1317–25.

https://doi.org/10.1164/rccm.202204-0671PP. PMID: 35914087. PMCID: PMC9746870.

6. Global initiative for chronic obstructive lung disease. 2025 GOLD Report: Global strategy for prevention, diagnosis and management of COPD. URL: https://goldcopd.org/2025-gold-report/ (date of access – 03.03.2025).

7. Клинические рекомендации. Стабильная ишемическая болезнь сердца. Ассоциация сердечно-сосудистых хирургов России, общероссийская общественная организация «Российское кардиологическое общество», автономная некоммерческая организация «Национальное общество по изучению атеросклероза», некоммерческое партнерство «Национальное общество по атеротромбозу», общероссийская общественная организация содействия развитию лучевой диагностики и терапии «Российское общество рентгенологов и радиологов», Российское научное общество специалистов по рентгенэндоваскулярной диагностике и лечению, Российское общество кардиосоматической реабилитации и вторичной профилактики, Российская ассоциация специалистов ультразвуковой диагностики в медицине. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 155_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/155_2 (дата обращения – 03.03.2025). (Clinical guidelines. Stable ischemic heart disease. Association of Cardiovascular Surgeons of Russia, Russian Cardiology Society, National Society for the Study of Atherosclerosis, National Society for Atherothrombosis, All-Russian public organization for the promotion of development of radiation diagnostics and therapy “Russian Society of Roentgenologists and Radiologists”, Russian Scientific Society of Specialists in Roentgen Endovascular Diagnostics and Treatment, Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, Russian Association of Specialists in Ultrasound Diagnostics in Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 155_2. URL: https://cr.minzdrav.gov.ru/preview-cr/155_2 (date of access – 03.03.2025) (In Russ.)).

8. Клинические рекомендации. Артериальная гипертензия у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», общероссийская общественная организация «Российское научное медицинское общество терапевтов». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 62_3. Доступ: https://cr.minzdrav.gov.ru/preview-cr/62_3 (дата обращения – 03.03.2025). (Clinical guidelines. Arterial hypertension in adults. Russian Cardiology Society, Russian Scientific Medical Society of Internal Medicine. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 62_3. URL: https://cr.minzdrav.gov.ru/preview-cr/62_3 (date of access – 03.03.2025) (In Russ.)).

9. Чаулин А.М., Григорьева Ю.В., Дупляков Д.В. Коморбидность хронической обструктивной болезни легких и сердечно-сосудистых заболеваний: общие факторы, патофизиологические механизмы и клиническое значение. Клиническая практика. 2020; 11(1): 112–121. (Chaulin A.M., Grigoryeva Yu.V., Duplyakov D.V. Comboridity of chronic obstructive pulmonary disease and cardiovascular diseases: General factors, pathophysiological mechanisms and clinical significance. Klinicheskaya praktika = Journal of Clinical Practice. 2020; 11(1): 112–121 (In Russ.)).

https://doi.org/10.17816/clinpract21218. EDN: NUSSNU.

10. Shi Y., Zhang J., Huang Y. Prediction of cardiovascular risk in patients with chronic obstructive pulmonary disease: A study of the national health and nutrition examination survey database. BMC Cardiovascul Disord. 2021; 21(1): 417.

https://doi.org/10.1186/s12872-021-02225-w. PMID: 34470611. PMCID: PMC8408968.

11. Fabbri L.M., Celli B.R., Agustí A. et al. COPD and multimorbidity: Recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023; 11(11): 1020–34.

https://doi.org/10.1016/S2213-2600(23)00261-8. PMID: 37696283.

12. Кароли Н.А., Ребров А.П. Маркеры дисфункции эндотелия у больных хронической обструктивной болезнью легких и ишемической болезнью сердца. Терапевтический архив. 2019; 91(3): 22–26. (Karoli N.A., Rebrov A.P. Endothelial dysfunction in patients with chronic obstructive pulmonary disease in combination with coronary heart disease. Terapevticheskiy arkhiv = Therapeutic Archive. 2019; 91(3): 22–26 (In Russ.)).

https://doi.org/10.26442/00403660.2019.03.000061. PMID: 31094454. EDN: NDWLVE.

13. Brassington K., Selemidis S., Bozinovski S., Vlahos R. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. Clin Sci. 2019; 133(7): 885–904.

https://doi.org/10.1042/CS20180316. PMID: 30979844. PMCID: PMC6465303.

14. Brassington K., Selemidis S., Bozinovski S., Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: Common mechanisms and novel therapeutics. Clin Sci. 2022; 136(6): 405–23.

https://doi.org/10.1042/CS20210835. PMID: 35319068. PMCID: PMC8968302.

15. Celli B.R., Fabbri L.M., Aaron S.D. et al. Differential diagnosis of suspected chronic obstructive pulmonary disease exacerbations in the acute care setting: Best practice. Am J Respir Crit Care Med. 2023; 207(9): 1134–44.

https://doi.org/10.1164/rccm.202209-1795CI. PMID: 36701677. PMCID: PMC10161746.

16. Vogelmeier C.F., Rhodes K., Garbe E. et al. Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: Results of the EXACOS-CV study in Germany. BMJ Open Respir Res. 2024; 11(1): e002153.

https://doi.org/10.1136/bmjresp-2023-002153. PMID: 38555102. PMCID: PMC10982767.

17. Singh D., Han M.K., Hawkins N.M. et al. Implications of cardiopulmonary risk for the management of COPD: A narrative review. Adv Ther. 2024; 41(6): 2151–67.

https://doi.org/10.1007/s12325-024-02855-4. PMID: 38664329. PMCID: PMC11133105.

18. Kunisaki K.M., Dransfield M.T., Anderson J.A. et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018; 198(1): 51–57.

https://doi.org/10.1164/rccm.201711-2239OC. PMID: 29442524. PMCID: PMC6913068.

19. Чазова И.Е., Невзорова В.А., Амбатьелло Л.Г. с соавт. Клинические рекомендации по диагностике и лечению пациентов с артериальной гипертонией и хронической обструктивной болезнью легких. Системные гипертензии. 2020; 17(3): 7–34. (Chazova I.E., Nevzorova V.A., Ambat’ello L.G. et al. Clinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease. Sistemnyye gipertenzii = Systemic Hypertension. 2020; 17(3): 7–34 (In Russ.)).

https://doi.org/10.26442/2075082X.2020.3.200294. EDN: EPBDGZ.

20. Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Lancet Respir Med. 2015; 3(8): 631–39.

https://doi.org/10.1016/S2213-2600(15)00241-6. PMID: 26208998.

21. Hurst J.R., Gale C.P. MACE in COPD: Addressing cardiopulmonary risk. Lancet Respir Med. 2024; 12(5): 345–48.

https://doi.org/10.1016/S2213-2600(24)00038-9. PMID: 38437859.

22. Graul E.L., Nordon C., Rhodes K. et al. Temporal risk of nonfatal cardiovascular events after chronic obstructive pulmonary disease exacerbation: A population-based study. Am J Respir Crit Care Med. 2024; 209(8): 960–72.

https://doi.org/10.1164/rccm.202307-1122OC. PMID: 38127850. PMCID: PMC11531205.

23. Graul E.L., Nordon C., Rhodes K. et al. Factors associated with non-fatal heart failure and atrial fibrillation or flutter within the first 30 days post COPD exacerbation: A nested case-control study. BMC Pulm Med. 2024; 24(1): 221.

https://doi.org/10.1186/s12890-024-03035-4. PMID: 38704538. PMCID: PMC11069200.

24. Marriott E., Singanayagam A., El-Awaisi J. Inflammation as the nexus: Exploring the link between acute myocardial infarction and chronic obstructive pulmonary disease. Front Cardiovasc Med. 2024; 11: 1362564.

https://doi.org/10.3389/fcvm.2024.1362564. PMID: 38450367. PMCID: PMC10915015

25. Humbert M., Kovacs G., Hoeper M.M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38): 3618–3731.

https://doi.org/10.1093/eurheartj/ehac237. PMID: 36017548.

26. Humbert M., Kovacs G., Hoeper M.M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023; 61(1): 2200879.

https://doi.org/10.1183/13993003.00879-2022. PMID: 36028254.

27. Kovacs G., Agusti A., Barbera J.A. et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype? Am J Respir Crit Care Med. 2018; 198(8): 1000–11.

https://doi.org/10.1164/rccm.201801-0095PP. PMID: 29746142.

28. Kovacs G., Avian A., Bachmaier G. et al. Severe pulmonary hypertension in COPD: Impact on survival and diagnostic approach. Chest. 2022; 162(1): 202–12.

https://doi.org/10.1016/j.chest.2022.01.031. PMID: 35092746. PMCID: PMC10808070.

29. Авдеев С.Н., Барбараш О.Л., Валиева З.С. с соавт. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(11): 170–250. (Avdeev S.N., Barbarash O.L., Valieva Z.S. et al. 2024 Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Clinical guidelines 2024. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024; 29(11): 170–250 (In Russ.)).

https://doi.org/10.15829/1560-4071-2024-6161. EDN: MYEOVA.

30. Parkin L., Williams S., Sharples K. et al. Dual versus single long-acting bronchodilator use could raise acute coronary syndrome risk by over 50%: A population-based nested case-control study. J Intern Med. 2021; 290(5): 1028–38.

https://doi.org/10.1111/joim.13348. PMID: 34289189. PMCID: PMC8596666.

31. Hawkins N.M., Petrie M.C., Macdonald M.R. et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol. 2011; 57(21): 2127–38.

https://doi.org/10.1016/j.jacc.2011.02.020. PMID: 21596228.

32. Dransfield M.T., Voelker H., Bhatt S.P. et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019; 381(24): 2304–14.

https://doi.org/10.1056/NEJMoa1908142. PMID: 31633896. PMCID: PMC7416529.

33. Yeoh S.E., Dewan P., Serenelli M. et al. Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. Eur J Heart Fail. 2022; 24(3): 529–38.

https://doi.org/10.1002/ejhf.2350. PMID: 34536265. PMCID: PMC10654446.

34. Dransfield M.T., McAllister D.A., Anderson J.A. et al. β-blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. An observational substudy of SUMMIT. Ann Am Thorac Soc. 2018; 15(5): 608–14.

https://doi.org/10.1513/AnnalsATS.201708-626OC. PMID: 29406772.

35. Yang Y.L., Xiang Z.J., Yang J.H. et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: A systematic review and meta-analysis. Eur Heart J. 2020; 41(46): 4415–22.

https://doi.org/10.1093/eurheartj/ehaa793. PMID: 33211823. PMCID: PMC7752251.

36. Gulea C., Zakeri R., Alderman V. et al. Beta-blocker therapy in patients with COPD: A systematic literature review and meta-analysis with multiple treatment comparison. Respir Res. 2021; 22(1): 64.

https://doi.org/10.1186/s12931-021-01661-8. PMID: 33622362. PMCID: PMC7903749.

37. Lu Y., Chang R., Yao J. et al. Effectiveness of long-term using statins in COPD – a network meta-analysis. Respir Res. 2019; 20(1): 17.

https://doi.org/10.1186/s12931-019-0984-3. PMID: 30674312. PMCID: PMC6343315.

38. Wu W.T., Chen C.Y. Protective effect of statins on pulmonary hypertension in chronic obstructive pulmonary disease patients: A nationwide retrospective, matched cohort study. Sci Rep. 2020; 10(1): 3104.

https://doi.org/10.1038/s41598-020-59828-0. PMID: 32080265. PMCID: PMC7033169.

39. Huang Y.J., Kao S., Kao L.T. et al. Association between statin use and exacerbation of chronic obstructive pulmonary disease among patients receiving corticosteroids. Int J Chron Obstruct Pulmon Dis. 2021; 16: 591–602.

https://doi.org/10.2147/COPD.S292026. PMID: 33716501. PMCID: PMC7944644.

40. Aaron C.P., Schwartz J.E., Hoffman E.A. et al. A longitudinal cohort study of aspirin use and progression of emphysema-like lung characteristics on CT imaging: The MESA lung study. Chest. 2018; 154(1): 41–50.

https://doi.org/10.1016/j.chest.2017.11.031. PMID: 29246770. PMCID: PMC6045779.

41. Fawzy A., Putcha N., Aaron C.P. et al. Aspirin use and respiratory morbidity in COPD: A propensity score-matched analysis in subpopulations and intermediate outcome measures in COPD study. Chest. 2019; 155(3): 519–27.

https://doi.org/10.1016/j.chest.2018.11.028. PMID: 30593776. PMCID: PMC6414789.

42. Andell P., James S.K., Cannon C.P. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: An analysis from the platelet inhibition and patient outcomes (PLATO) trial. J Am Heart Assoc. 2015; 4(10): e002490.

https://doi.org/10.1161/JAHA.115.002490. PMID: 26452988. PMCID: PMC4845124.

43. Vasileiadis I.E., Goudis C.A., Giannakopoulou P.T., Liu T. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers: A promising medication for chronic obstructive pulmonary disease? COPD. 2018; 15(2): 148–56.

https://doi.org/10.1080/15412555.2018.1432034. PMID: 29521545.

44. Tejwani V., Fawzy A., Putcha N. et al. Emphysema progression and lung function decline among angiotensin converting enzyme inhibitors and angiotensin-receptor blockade users in the copdgene cohort. Chest. 2021; 160(4): 1245–54.

https://doi.org/10.1016/j.chest.2021.05.007. PMID: 34029566. PMCID: PMC8546238.

45. Dauriat G., Reynaud-Gaubert M., Cottin V. et al. Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. J Heart Lung Transplant. 2021; 40(9): 1009–18.

https://doi.org/10.1016/j.healun.2021.04.021. PMID: 34218966.

46. Vizza C.D., Hoeper M.M., Huscher D. et al. Pulmonary hypertension in patients with COPD: Results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Chest. 2021; 160(2): 678–89.

https://doi.org/10.1016/j.chest.2021.02.012. PMID: 33581097.

47. Nathan S.D., Argula R., Trivieri M.G. et al. Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results. Eur Respir J. 2024; 63(6): 2400172.

https://doi.org/10.1183/13993003.00172-2024. PMID: 38811045. PMCID: PMC11154754.

48. Almutairi S., Kalloush H.M., Manoon N.A., Bardaweel S.K. Matrix metalloproteinases inhibitors in cancer treatment: An updated review (2013–2023). Molecules. 2023; 28(14): 5567.

https://doi.org/10.3390/molecules28145567. PMID: 37513440. PMCID: PMC10384300.

49. Maclagan L.C., Croxford R., Chu A. et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J. 2023; 62(2): 2202364.

https://doi.org/10.1183/13993003.02364-2022. PMID: 37385658.

50. Клинические рекомендации. Нарушения липидного обмена. Общероссийская общественная организация «Российское кардиологическое общество», Российская ассоциация эндокринологов, общероссийская общественная организация «Российское научное медицинское общество терапевтов», автономная некоммерческая организация «Национальное общество по изучению атеросклероза», общероссийская общественная организация «Российская ассоциация геронтологов и гериатров», Евразийское общество терапевтов, Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР), Евразийская ассоциация кардиологов. Рубрикатор клинических рекомендаций Минздрава России. 2023. ID: 752_1. Доступ: https://cr.minzdrav.gov.ru/preview-cr/752_1 (дата обращения – 03.03.2025). (Clinical guidelines. Lipid metabolism disorders. Russian Society of Cardiology, Russian Association of Endocrinologists, Russian Scientific Medical Society of Internal Medicine, National Society for the Study of Atherosclerosis, Russian Association of Gerontologists and Geriatricians, Eurasian Association of Therapists, Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention (RosOKR), Eurasian Association of Cardiologists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2023. ID: 752_1. URL: https://cr.minzdrav.gov.ru/preview-cr/752_1 (date of access – 03.03.2025) (In Russ.)).

51. Agusti A., Böhm M., Celli B. et al. GOLD COPD DOCUMENT 2023: A brief update for practicing cardiologists. Clin Res Cardiol. 2024; 113(2): 195–204.

https://doi.org/10.1007/s00392-023-02217-0. PMID: 37233751. PMCID: PMC10215047.